Skip to main content Skip to secondary navigation

Docket #: S12-506

Novel PET imaging agents for the detection of CA6 epitope in-vivo

Stanford researchers have developed new imaging agents for the detection of the CA6 epitope in vivo in cancer patients. This PET based imaging modality will be able to detect and stratify CA6 expression in vivo and can be used for patient stratification and early therapy monitoring of CA6-targeted therapies. This invention is a companion diagnostic for CA6 targeting antibody-drug conjugate (ADC) therapy. Targeted therapies may benefit from a companion diagnostic which can help select the patient whom could benefit the most from this therapy and allow for therapy monitoring in early time points after therapy initiation.

Stage of Research:

  • Conducted pre-clinical evaluation of one of the derivatives (B-Fab) at Stanford
  • These studies suggest that 64Cu-DOTA-B-Fab may be a suitable companion diagnostic for SAR566658 in cancer patients and requires further investigation
    Human clinical trials in ovarian cancer patients to start early 2015
  • Applications

    • PET based imaging modality which enables:
      • Patient stratification for CA6 expression to enable the selection of suitable patients for clinical trials
      • Early therapy efficacy monitoring in patients receiving the SAR566658 ADC or other CA6 targeted therapies

    Advantages

    • Non-invasive method for CA6 evaluation in patients
    • Companion diagnostic for CA6 targeting antibody-drug conjugate (ADC) therapy
    • Imaging can be done as early as 6 hours post injection of the racer (in mice)

    Publications

    Related Links

    Patents

    Similar Technologies

    Explore similar technologies by keyword: